Loading...
01/11 03:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture with both positive and negative aspects. While there is growth in certain areas like the Puebla facility and Gamma Knife revenue, overall revenue and gross margins have declined year-over-year. The Q&A section reveals concerns about market valuation and management's vague responses. Despite some improvements in specific metrics, the lack of clear guidance and the company's thin trading volume suggest a neutral market reaction. Without a clear strategy to address these issues, the stock price is likely to remain stable in the short term.
Third Quarter Revenue $7.2 million, a 2.5% increase year-over-year, driven by increased procedures at the new facility in Puebla, Mexico.
Direct Patient Services Revenue $4 million, a 9.4% increase year-over-year, primarily due to increased procedures at the Puebla, Mexico facility.
Medical Equipment Leasing Revenue $3.1 million, a decrease from $3.3 million year-over-year, due to lower proton beam radiation therapy volumes.
Gamma Knife Revenue $2.1 million, a 16% increase year-over-year, with procedures increasing from 218 to 231.
Proton Beam Radiation Therapy Revenue $2.1 million, a 10.8% increase from Q2 2025, but an 8.1% decrease in therapy fractions year-over-year due to cyclical fluctuations.
Linear Accelerator (LINAC) Systems Revenue $2.9 million, a 15.9% increase from Q2 2025 and a 51.2% increase year-over-year, driven by operations in Puebla, Mexico and Rhode Island.
Gross Margins 22.1%, a 16% year-over-year increase to $1.6 million, primarily due to higher treatment volumes.
Operating Income Loss of $344,000, an improvement from a loss of $889,000 year-over-year.
Net Loss $55,000, an improvement from a net loss of $207,000 year-over-year.
Adjusted EBITDA $1.9 million, a 41% increase year-over-year from $1.4 million.
Year-to-Date Revenue $20.4 million, a 5.6% increase year-over-year, driven by Rhode Island and Puebla, Mexico operations.
Direct Patient Care Services Revenue (Year-to-Date) $10.7 million, a 36.5% increase year-over-year, driven by Rhode Island and Puebla, Mexico operations.
Equipment Leasing Revenue (Year-to-Date) $9.7 million, a decrease from $11.5 million year-over-year, due to expired contracts and lower PBRT volumes.
Gamma Knife Revenue (Year-to-Date) $6.8 million, a 4.2% decrease year-over-year, due to expired contracts and lower PBRT volumes.
Proton Beam Radiation Therapy Revenue (Year-to-Date) $5.7 million, a 23% decrease year-over-year, due to cyclical fluctuations.
Linear Accelerator (LINAC) Systems Revenue (Year-to-Date) $9.7 million, a significant increase from $4.8 million year-over-year, driven by Rhode Island and Puebla, Mexico operations.
Gross Margin (Year-to-Date) $4.2 million, a 20.4% decrease year-over-year, reflecting lower volumes and increased operating costs.
Operating Loss (Year-to-Date) $2.2 million, compared to a loss of $975,000 year-over-year.
Net Loss (Year-to-Date) $922,000, compared to net income of $3.5 million year-over-year, primarily due to a $3.9 million bargain purchase gain in 2024.
Adjusted EBITDA (Year-to-Date) $4.6 million, compared to $5.1 million year-over-year.
New Radiation Therapy Treatment Center in Puebla, Mexico: Achieved 263% annual revenue growth, showcasing significant growth potential.
Gamma Knife Revenue: Increased by almost 17% year-over-year, indicating strong performance in this segment.
Expansion in Rhode Island: Acquired three cancer treatment centers and planning to construct two new facilities, including the first proton beam radiation therapy center in the state.
International Expansion: Opened a new center in Puebla, Mexico, and planning to open a Gamma Knife center in Guadalajara, Mexico, by Q2 2026.
Transition to Direct Patient Care Services: Revenue from direct patient care services now constitutes 56% of total revenue, reflecting a strategic shift from equipment leasing.
Operational Efficiencies: Gross margins increased by 16%, and operating loss improved by 92% year-over-year.
Growth Strategy: Focused on long-term shareholder value through revenue growth, operational efficiencies, and strategic expansions.
Business Development Initiatives: Emphasizing physician engagement and partnerships to drive treatment volumes and market share.
Revenue from equipment leasing segment: Decreased to $9.7 million from $11.5 million in the first 9 months of 2024, primarily due to the expiration of 3 customer contracts since Q4 2024 and lower proton beam radiation therapy (PBRT) volumes.
Gamma Knife revenue: Declined 4.2% to $6.8 million for the first 9 months of 2025 compared to $7.1 million in the first 9 months of 2024, with the number of procedures dropping from 831 to 703 due to contract expirations and lower volumes.
Proton beam radiation therapy (PBRT) revenue: Decreased 23% to $5.7 million in the first 9 months of 2025 compared to $7.4 million in the first 9 months of 2024, with therapy fractions declining 18% due to cyclical fluctuations.
Gross margin: Declined to $4.2 million for the first 9 months of 2025 compared to $6 million in the same period of 2024, reflecting lower volumes and increased operating costs from the shift to direct patient services.
Net loss: Increased to $922,000 for the first 9 months of 2025 compared to net income of $3.5 million in the same period of 2024, primarily due to the absence of a $3.9 million bargain purchase gain from the Rhode Island acquisition in 2024.
Cash and cash equivalents: Declined to $5.3 million as of September 30, 2025, from $11.3 million at December 31, 2024, due to $7.5 million spent on capital expenditures for new facilities.
Revenue Growth: The company expects continued growth in treatment volumes, particularly in Rhode Island, and anticipates additional growth in the fourth quarter of 2025. The new radiation therapy treatment center in Puebla, Mexico, showed a 263% annual revenue growth, and the company expects stronger international growth from additional treatment volumes in Ecuador, Peru, and Mexico.
New Facility Openings: The company plans to open a Gamma Knife center in Guadalajara, Mexico, in the second quarter of 2026, which will be the only Esprit Gamma Knife in Mexico. Additionally, the company is constructing a fourth radiation therapy center in Bristol, Rhode Island, and the first proton beam radiation therapy center in Rhode Island.
Market Expansion: The company is focused on expanding its footprint in Rhode Island and internationally, with growth opportunities in its existing and new centers in Mexico, Peru, and Ecuador.
Operational Efficiency: The company remains focused on improving profitability through operational efficiencies and expects steady growth in treatment volumes through physician engagement and partnerships with health system joint ventures.
The selected topic was not discussed during the call.
The earnings call presents a mixed picture with both positive and negative aspects. While there is growth in certain areas like the Puebla facility and Gamma Knife revenue, overall revenue and gross margins have declined year-over-year. The Q&A section reveals concerns about market valuation and management's vague responses. Despite some improvements in specific metrics, the lack of clear guidance and the company's thin trading volume suggest a neutral market reaction. Without a clear strategy to address these issues, the stock price is likely to remain stable in the short term.
The earnings call reveals mixed signals: solid revenue growth and international expansion are offset by declining margins, increased expenses, and revenue drops in key areas. Although management shows optimism, the financials indicate challenges. Despite sequential improvements, year-over-year declines in key metrics and contract expirations raise concerns. The Q&A section highlights strategic staffing and partnerships, but these are not immediate catalysts. Without clear market cap data, a neutral rating is prudent, anticipating limited stock movement within -2% to 2% range due to offsetting positive and negative factors.
Despite strong revenue growth in direct patient services and international expansion, the earnings call revealed several negative factors: an EPS miss, declining treatment volumes, and increased operational expenses leading to a significant drop in adjusted EBITDA. The Q&A highlighted concerns about regulatory changes and management's vague responses added uncertainty. The lack of shareholder return initiatives further dampens sentiment. Overall, these factors suggest a negative stock price reaction in the coming weeks.
The earnings call reveals a mixed financial performance with some growth in revenue but significant declines in margins and increased operational costs. The lack of shareholder return plans and potential risks from regulatory challenges and competitive pressures further contribute to a negative outlook. The Q&A section does not alleviate concerns, as management's responses on regulatory impacts are vague. The overall sentiment is negative, with a likely stock price decrease of -2% to -8% in the coming weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
